CGM-guided dietary titration improves Time in Range in hepatic GSD patients
In interventional settings, CGM-guided dietary titration improved Time in Range from 72% to 86% in gene therapy trials, and reduced serum triglycerides and liver size. CGM consistently identified asymptomatic hypoglycemia, with adult cohorts spending up to 12% of time below range despite normal spot checks.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
CGM-guided dietary titration improves Time in Range in hepatic GSD patients The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
CGM-guided dietary titration improves Time in Range in hepatic GSD patients
This conclusion is most relevant to: Patients with hepatic Glycogen Storage Diseases (GSD), predominantly GSD Ia, Ib and III.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes. (Endocrinology, diabetes & metabolism, 2026) —
How It Works
The proposed biological pathway:
- ▸CGM detects asymptomatic hypoglycemic excursions missed by intermittent monitoring
- ▸Data guides dietary adjustments to stabilize glucose levels
- ▸Improved glucose control reduces metabolic abnormalities (triglycerides, liver size)
- ▸Result: Increased Time in Range and improved clinical outcomes
Who Might Benefit
Evidence fit by population:
- ▸Patients with hepatic Glycogen Storage Diseases (GSD), predominantly GSD Ia, Ib and III
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Sensor performance showed a positive bias in the hypoglycemic range, potentially masking severe neuroglycopenia
- ▸CGM introduced 'alarm fatigue' from false-positive alerts, impacting patient burden
Frequently Asked Questions
What is the main benefit of CGM in GSD patients?▼
CGM offers superior sensitivity for detecting occult hypoglycemia and guiding therapy, shifting management from reactive treatment to proactive stabilization.
How much did Time in Range improve with CGM-guided titration?▼
In gene therapy trials, Time in Range improved from 72% to 86%.
What are the limitations of CGM in GSD?▼
Sensor inaccuracy at lower glucose levels can mask severe neuroglycopenia, and false-positive alerts cause alarm fatigue.
Which GSD subtypes were studied?▼
The review predominantly included GSD Ia, Ib and III.
References
- 1.Mohsenipour R, Abbasi F, Ghaderian MS, Dehkordi AK, Abdolahpour S, Akbari K. “Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes..” Endocrinology, diabetes & metabolism, 2026. PMID: 42394382 DOI: 10.1002/edm2.70274